Stay up-to-date on the Foundation for Sarcoidosis (FSR)'s latest activities and learn about the ways that FSR is driving progress and accelerating research towards a cure.
FSR Reports
FSR has undertaken a comprehensive process to develop a new Research Agenda that will guide its funding priorities and strategic direction. This initiative comes at a critical time, as sarcoidosis affects approximately 1.2 million people worldwide, and approximately 175,000-200,000 in the United States. Sarcoidosis was first discovered over 150 years ago and yet little progress has been made toward a significant breakthrough in the scientific understanding of the disease and the therapeutic options.
To address this concern, FSR has endeavored to create a robust Research Agenda aimed at addressing gaps in sarcoidosis research. This Research Agenda represents a strategic and measurable approach toward the achievement of our mission to accelerate progress toward improved treatments and a possible cure for sarcoidosis.
On October 28, 2024, the Foundation for Sarcoidosis Research hosted the Externally-Led Patient Focused Drug Development (EL-PFDD) Meeting—an interactive, virtual event where patients and caregivers shared their experiences, unmet needs, and treatment priorities.
The resulting 50-page Voice of the Patient Report captures these insights, reflecting the real-world impact of sarcoidosis and guiding future research and therapy development. This report amplifies the voices of patients and caregivers, providing valuable perspective for healthcare providers, researchers, and drug developers to ensure that patient needs remain at the center of progress.
FSR is excited to announce the release of The FSR-SARC Patient Registry Report (FSR Registry Report), “Living with Sarcoidosis – Insights from the FSR-SARC Patient Registry (FSR Registry)."
This global, patient-reported outcomes program incorporates dates from 2015-2025. For a decade, the FSR Registry has gathered crucial information from individuals living with sarcoidosis around the world. This online patient registry is helping researchers uncover patterns in the disease and identify ways to improve care and quality of life.
Posters and Abstracts
Partner Joint Publications
Toolkits
White Papers
Annual Updates
Press Releases
FSR Blog
WHO Air Quality Guidelines Update: Health experts urge nations to implement ambitious air pollution reduction policies
Health experts urge nations to implement ambitious air pollution reduction policies Health experts and patient representative groups have issued a joint statement urging nations toLearn More
aTyr Pharma Announces Positive Data from Phase 1b/2a Pulmonary Sarcoidosis Clinical Trial
On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to haveLearn More
Living with ILD: A Sarcoidosis Patient Perspective
My journey with Interstitial Lung Disease (ILD) started about 15 years ago, although I did not know it at the time, nor did theLearn More
COVID-19 Vaccine Boosters for Immunocompromised Patients
Sarcoidosis does not automatically indicate an immunocompromised diagnosis. FSR cannot determine or provide recommendations for your individual immunocompromised status. Please consult your physician forLearn More
Introducing the FSR Patient Speakers’ Bureau
We are thrilled to announce the formation of our new FSR Patient Speakers’ Bureau! This bureau consists of 14 experienced and trained sarcoidosisLearn More
FSR-MNK Sarcoidosis Research Fellow Awarded for 2021-2023
The Foundation for Sarcoidosis Research (FSR) is pleased to announce the Foundation for Sarcoidosis Research Fellowship Grant for 2021-2023 is being awarded to Dr.Learn More
FSR Welcomes Three New Members to its Board of Directors
The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients,Learn More
FSR’s Women of Color Committee
Foundation for Sarcoidosis Research is seeking applicants for our first Women of Color Committee. African Americans in the U.S. have been the group mostLearn More
COVID-19 Vaccine and Sarcoidosis: a survey of vaccination rate, tolerance and barriers
Authors: Arindam Singha, MD1; Tricha Shivas, MBe2 ; Elliot D. Crouser, MD1 Since it was declared a global pandemic in March of 2020,Learn More
Quick links
Check out these recent updates!